What Are the Requirements for Conducting a Clinical Investigation in Saudi Arabia?

Conducting clinical investigations in Saudi Arabia requires approval from the Saudi Food and Drug Authority (SFDA), submission of comprehensive documentation including the protocol and investigator qualifications, and adherence to Good Clinical Practice standards. The process typically takes 60-90 days for approval, depending on the complexity of the study and the completeness of the application.

Furthermore, manufacturers must work with qualified local investigators and maintain ongoing compliance throughout the study duration. The SFDA has aligned its clinical investigation requirements with international standards to ensure patient safety and data integrity while facilitating medical device innovation in the Kingdom.

How long does SFDA approval take for clinical investigations?

SFDA approval for clinical investigations typically takes 60 to 90 days from the submission of a complete application. The timeline depends on the complexity of the medical device, study design, and completeness of the submitted documentation.

Additionally, the review process may extend beyond 90 days if the SFDA requests additional information or clarification during its assessment. The authority conducts a thorough evaluation of the clinical investigation protocol, investigator qualifications, facility capabilities, and patient safety measures before granting approval.

Manufacturers can expedite the approval process by ensuring their initial submission includes all required documentation and meets SFDA formatting requirements. Working with an experienced Saudi Arabia Authorized Representative can help streamline the submission process and reduce the likelihood of delays due to incomplete or improperly formatted applications.

What documentation must be submitted to SFDA for clinical investigation approval?

The SFDA requires a comprehensive clinical investigation application that includes the study protocol, investigator brochure, informed consent forms, investigator qualifications, and facility certifications. All documentation must be submitted in Arabic or English, with proper translations where required.

The complete documentation package must include several critical components. The clinical investigation protocol should detail the study objectives, methodology, inclusion and exclusion criteria, primary and secondary endpoints, and statistical analysis plan. The investigator brochure must provide comprehensive information about the medical device, including preclinical data, known risks, and any previous clinical experience.

Furthermore, the application requires detailed information about the principal investigator and sub-investigators, including their curriculum vitae, medical licenses, and Good Clinical Practice training certificates. The clinical site must provide facility documentation demonstrating adequate infrastructure, equipment, and staff to conduct the investigation safely and effectively.

Additional required documents include the informed consent forms in Arabic, ethics committee approval, insurance coverage documentation, and a comprehensive risk management plan. The manufacturer must also submit technical documentation about the medical device, including design specifications, manufacturing information, and quality management system certificates.

Who can serve as a principal investigator for clinical studies in Saudi Arabia?

Principal investigators for clinical studies in Saudi Arabia must be licensed physicians with appropriate medical specialization relevant to the study indication and documented experience in clinical research. They must hold valid Saudi medical licenses and demonstrate Good Clinical Practice training certification.

The SFDA requires principal investigators to possess specific qualifications that ensure patient safety and study integrity. Investigators must have relevant clinical experience in the therapeutic area being studied, with a minimum of three years of clinical practice in their specialty. They should demonstrate previous experience conducting clinical research, either as principal investigators or sub-investigators in previous studies.

Additionally, principal investigators must be affiliated with an approved clinical research facility that meets SFDA standards for conducting clinical investigations. The facility should have adequate infrastructure, including appropriate patient care areas, equipment for study procedures, and secure storage for investigational devices and study documentation.

The investigator must also demonstrate ongoing professional development through continuing medical education and maintain current knowledge of relevant therapeutic areas. They are responsible for ensuring compliance with the study protocol, patient safety monitoring, and accurate data collection throughout the investigation.

What are the ongoing compliance obligations during a clinical investigation?

Ongoing compliance obligations during clinical investigations include regular safety reporting to the SFDA, maintaining accurate study records, adhering to the approved protocol, and submitting periodic progress reports. Investigators must report serious adverse events within 24 hours and provide annual safety updates.

Throughout the study duration, investigators must maintain comprehensive documentation of all study activities, including patient enrollment, device usage, adverse events, and protocol deviations. The study team must ensure that all data collection follows Good Clinical Practice standards and that patient confidentiality is maintained according to local privacy regulations.

Regular monitoring visits are required to verify data accuracy and ensure protocol compliance. The sponsor or its designated representative must conduct these visits according to a predetermined monitoring plan, documenting any findings and implementing corrective actions when necessary.

Furthermore, investigators must maintain ongoing communication with the SFDA regarding any significant changes to the study protocol, investigator team, or clinical site. Any modifications require prior approval before implementation, and the study team must document all changes appropriately in the study files.

The clinical site must also maintain proper storage and handling of investigational devices, ensuring traceability and accountability throughout the study. Regular inventory reconciliation and device return procedures must be documented according to SFDA requirements and the approved study protocol.

How MedEnvoy Helps with Clinical Investigation Requirements in Saudi Arabia

MedEnvoy provides comprehensive support for manufacturers seeking to conduct clinical investigations in Saudi Arabia through expert regulatory guidance and In-Country Representation services. Our experienced team helps navigate the complex SFDA approval process while ensuring full compliance throughout the study duration.

• Complete application preparation and submission to SFDA with proper documentation formatting
• Coordination with qualified local investigators and clinical research facilities
• Ongoing regulatory support throughout the clinical investigation lifecycle
• Safety reporting and adverse event management according to SFDA requirements
• Protocol amendment submissions and regulatory correspondence handling

Ready to begin your clinical investigation in Saudi Arabia? Contact our regulatory experts to discuss your specific requirements and develop a comprehensive strategy for successful SFDA approval and study execution.

Related Articles

• Why Does International Expansion Take Longer Than Expected for US Device Companies?
• How Do I Terminate a Swiss Authorized Representative Agreement?
• What Are the Hidden Costs of Selling in Europe?
• How Do I Sell Medical Devices in Poland?
• How much does EUDAMED registration cost?